Programmed cell death: The influence of CD40, CD95 (Fas or APO-I) and their ligands

Medical Oncology

Volumn 15, Issue 1, 1998, Pages 15-19

  Laytragoon Lewin, N ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

CD40; CD40L; CD95; CD95L; Programmed cell death

Indexed keywords

CD40 ANTIGEN; FAS ANTIGEN; LIGAND; MONOCLONAL ANTIBODY; NERVE GROWTH FACTOR; PROTEIN BCL 2; TUMOR NECROSIS FACTOR ALPHA;

ANTIGEN EXPRESSION; APOPTOSIS; CANCER CELL; CHRONIC LYMPHATIC LEUKEMIA; EMBRYO DEVELOPMENT; HUMAN; HUMAN CELL; LETHALITY; MULTIPLE MYELOMA; POSTNATAL DEVELOPMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; REVIEW;

EID: 0031837312     PISSN: 07360118     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02787339     Document Type: Review

References (42)

1. Krammer PH, Behrmann I, Daniel P, Dhein J, Debatin K. Regulation of apoptosis in the immune system. Curr Opin Immunol 1994; 6: 279-289.
2. MacLennan ICM. Germinal centers. Annu Rev Immunol 1994; 12: 117-139.
3. Gordon J, Katira A, Holder M, MacDonald I, Pound J. Central role of CD40 and its ligand in B lymphocyte response to T dependent antigens. Cell Mol Biol 1994; 40: 1-12.
4. Öhm A et al. Purification and molecular cloning of the Apo-1 cell surface antigen, a member of the tumor necrosis factor/nerve growth factor receptor superfamily. J Biol Chem 1992; 267: 10709-10715.
5. Lagresle C, Bella C, Daniel P, Krammer PH, Defrance T. Regulation of germinal center B cell differentiation. Role of the human Apo1/Fas (CD95) molecule. J Immunol 1995; 154: 5746-5756.
6. Kägi D et al. Fas and perforin pathways as major mechanisms of T cell-mediated cytotoxicity. Science 1994; 265: 528-530.
7. Ramsdell F et al. Differential ability of Th1 and Th2 T cells to undergo activation induced cell death. Int Immunol 1994; 6: 1545-1553.
8. Hahn S, Gehri R, Erb P. Mechanism and biological significance of CD4 mediated cytotoxicity. Immunol Rev 1995; 146: 57-79.
9. Sad S et al. Cytotoxic and weak CD40 ligand expression of CD8+ type 2 cytotoxic T cells restricts their potential B cell helper activity. Eur J Immunol 1997; 27: 914-922.
10. Vergelli M et al. Human autoreactive CD4 + T cell clones use perforin- or Fas/Fas ligand- mediated pathways for target cell lysis. J Immunol 1997; 158: 2756-2761.
11. Rensing-Ehl A et al. Local Fas/Apo-1 (CD95) ligand-mediated tumor cell killing in vivo. Eur J Immunol 1995; 25: 2253-2258.
12. Nagata S, Goldstein P. The Fas death factor. Science 1995; 267: 1449-1456.
13. Russell J, Rush B, Weaver C, Wang R. Mature T cells of autoimmune lpr/lpr mice have a defect in antigen-stimulated suicide. Proc Natl Acad Sci USA 1993; 90: 4409-4413.
14. Reap E, Leslie D, Abrahams M, Eisenberg R, Cohen P. Apoptosis abnormalities of splenic lymphocytes in autoimmune lpr and gld mice. J Immunol 1995; 154: 936-943.
15. Stamenkovic I, Clark E, Seed B. A B-lymphocyte activation molecule related to the nerve growth factor receptor and induced by cytokines in carcinomas. EMBO J 1989; 8: 1403-1410.
16. Uckum F et al. Stimulation of protein tyrosine phosphorylation, phosphoinositide turnover and multiple previously unidentified serine thyreonine-specific protein kinases by the pan-B cell receptor CD40/Bp50 at discrete development stages of human B cell ontogeny. J Biol Chem 1991; 266: 17478-17485.
17. Schriever F et al. Isolation human follicular dendritic cells display a unique antigenic phenotype. J Exp Med 1989; 169: 2043-2058.
18. Liu Y et al. Mechanism of antigen-driven selection in germinal centres. Nature 1989; 342: 929-931.
19. Banchereau J, de Paoli P, Valle A, Garcia E, Roussel F. Long term human B cell lines dependent on Interleukin -4 and antibody to CD40. Science 1991; 251: 70-72.
20. Armitage R et al. Molecular and biological characterization of a murine ligand for CD40. Nature 1992; 357: 80-82.
21. Banchereau J et al. The CD40 antigen and its ligand. Ann Rev Immunol 1994; 12: 881-922.
22. Faris M, Gaskin F, Parsons J, Fu S. CD40 signaling pathway: anti-CD40 monoclonal antibody induces rapid dephosphorylation and phosphorylation of tyrosine-phosphorylated proteins including protein tyrosine kinase lyn, fyn and syk and the appearance of a 28-kD tyrosine-phosphorylated protein. J Exp Med 1994; 179: 1923-1931.
23. Lederman S, Yellin MJ, Cleary AM, Pernis A, Inghirami G, Cohn LE, Covey LR, Lee JJ, Rothman P, Chess L. T-BAM/CD40-L on helper T lymphocytes augments lymphokine-induced B cell Ig isotype switch recombination and rescues B cells from programmed cell death. J Immunol 1994; 152: 2163-2171.
24. Spriggs M, Fanslow R, Armitage R, Belmont J. The biology of the human ligand for CD40. J Clin Immunol 1993; 13: 373-380.
25. Foy T et al. GP 39-CD40 interactions are essential for germinal center formation and the development of B cell memory. J Exp Med 1994; 180: 157-163.
26. Kindler V, Zubler R. Memory but not naive, peripheral blood B lymphocytes differentiate into Ig-secreting cells after CD40 Iigation and costimulation with IL4 and the differentiation factors IL2, IL10 and IL3. J Immunol 1997; 159: 2084-2090.
27. Lagresle C, Mondiere P, Bella C, Krammer PH, Defrance T. Concurrent engagement of CD40 and the antigen receptor protect naive and memory human B cells from Apo-1/Fas mediated apoptosis. J Exp Med 1996; 183: 1377-1388.
28. Schattner E et al. CD40 Iigation induces Apo-I/Fas expression on human B lymphocytes and facilitates apoptosis through the Apo-1/Fas pathway. J Exp Med 1995; 182: 1557-1565.
29. DiSanto J, Bonnefoy J, Gauchat J, Fisher A, de Saint Basile G. CD40 ligand mutation in X-linked immunodeficiency with hyper IgM. Nature (Lond.) 1993; 361: 541-543.
30. Zang L, Miller R, Zang J. Characterization of apoptosis-resistant antigen-specific T cells in vivo. J Exp Med 1996; 183: 2065-2070.
31. Mapara M et al. Apo-I mediated apoptosis or proliferation in human chronic B lymphocytic leukaemia: correlation with Bcl-2 oncogene expression. Eur J Immunol 1993; 23: 702-708.
32. Shima Y, Nishimoto N, Yoshizaki K, Kishimoto T. Fas antigen/Apo-I (CD95) expression on myeloma cells. Leukaemia and Lymphoma 1996; 23: 521-531.
33. Kondo T, Suda T, Fukuyama H, Adachi M, Nagata S. Essential roles of Fas ligand in the development of hepatitis. Nature Med 1997; 3: 409-413.
34. Notarangelo L, Duse M, Ugazio A. Immunodeficiency with hyper-IgM (HIM). Immunodefic Rev 1992; 3: 101-121.
35. Fisher G et al. Dominant interfering Fas gene mutations impair apoptosis in a human autoimmune lymphoproliferative syndrome. Cell 1995; 81: 935-946.
36. Rieux-Laucat F et al. Mutations in Fas associated with human lymphoproliferation syndrome and autoimmunity. Science (Wash, DC)1995; 268: 1347-1349.
37. Weller M et al. Anti-Fas/Apo-I antibody-mediated apoptosis of cultured human glioma cells. Induction and modulation of sensitivity by cytokines. J Clin Invest 1994; 94: 954-964.
38. Strand S et al. Lymphocyte apoptosis induced by CD95 (Apol/Fas) ligand-expressing tumor cells - a mechanism of immune evasion?. Nature Med 1996; 2: 1361-1366.
39. O'Connell J, O'Sullivan G, Collins J, Shanahan F. The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand. J Exp Med 1996; 184: 1075-1082.
40. Hahne M et al. Melanoma cell expression of Fas (Apo-1/CD95) ligand: implications of tumor immune escape. Science 1996; 274: 1363-1366.
41. Villunger A et al. Constitutive expression of Fas (Apo-1/CD95) ligand on multiple myeloma cells: a potential mechanism of tumor-induced suppression of immune surveillance. Blood 1997; 90: 12-20.
42. Sato K et al. An aggressive nasal lymphoma accompanied by high levels of soluble Fas ligand. Br J Haematol 1996; 94: 379-382.